SEC Form 4																
FO	RM 4	UNITEI	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See				pursuar	E CHANGES nt to Section 16(a) o ction 30(h) of the In	ecuritie		HIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5								
1. Name and Address of Reporting Person [*] McIlwain Matthew S					er Name and Ticke tilus Biotechn			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
(Last) (First) (Middle)					e of Earliest Transa /2023	ay/Year)		Officer (giv below)	Other below)	(specify)						
C/O NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVE. E.					nendment, Date of	(Month/Day/Ye	6. Indi Line) X	· · · · · · · · · · · · · · · · · · ·								
(Street) SEATTLE	WA	98102									Form filed Person	by Mor	e than One Rep	orting		
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10								r writter	ı plan that is inten	ded to		
		Table I - Noi	n-Derivat	tive S	ecurities Acq	uired,	Disp	osed of, o	r Ben	eficially	Owned					
Date			2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Follo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	(A) or (D)	Price	Reported Transaction((Instr. 3 and 4			(Instr. 4)			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			ve es ed	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$3.97	06/15/2023		А		45,000		(1)	06/15/2033	Common Stock	45,000	\$0	45,000	D	

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Remarks:

in-Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

/s/ Anna Mowry, as Attorney-06/16/2023 ** Signature of Reporting Person Date